A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints

作者：Aldo Moreno‐Ulloa, Nayelli Nájera, Marcela Hernández-Ortega, Israel Ramírez‐Sánchez, Pam R. Taub, Yongxuan Su, Ernesto Beltrán‐Partida, Guillermo Ceballos, Sundeep Dugar, George F. Schreiner, Brookie M. Best, Theodore P. Ciaraldi, Robert R. Henry, Francisco Villarreal · 发表于：Food & Function · 年份：2017 · DOI：10.1039/c7fo01028a · 被引用次数：24 · 研究领域：Phytochemicals and Antioxidant Activities、Pharmacology and Obesity Treatment、Antioxidant Activity and Oxidative Stress

. Results indicate that (+)-Epi evidences a favorable PK and safety profile. Using a pre-clinical model, the compound positively modulates metabolism, which may link to mitochondrial effects. Effects are not due to general antioxidant actions, as Cat yielded no effects.